We review a recent article published in Cell discussing the conservative bias of life scientists and how that negatively impacts the diversity in research.
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action, toxicity and potential targets for novel compounds. In this case study we outline how we used the animal model C. elegans to perform a set of specific experiments designed by our experts to provide rapid and reliable data based on our customer’s priorities. Using the data that we provided, our customer was able to apply for multiple patents in a timely manner.
Are you starting a new C. elegans lab and feeling overwhelmed with starting from scratch? We want to help make this process as smooth as possible for you, so we have compiled a list of what our scientists believe to be the most essential items for you to have in order to get your lab […]
Animal testing in the research-based pharmaceutical industry has been reduced in recent years both for ethical and cost reasons. However, it is still a staple when it comes to discovering new compounds directed at improving human health. Recently, I have come across more and more researchers who are looking for the most efficient way to […]
Investment will be used to further develop the Company’s Precisome platform for functional analysis New investment led by Oregon Venture Fund Dr Stephen Turner appointed as Senior Research Fellow to help lead company expansion Eugene, Oregon, USA, 29 July 2019: NemaMetrix, an Oregon-based company that provides phenotyping and functional analysis using C. elegans […]